Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open in green
Wed, 2 Sep 09:30 am

The major Asian stock markets have opened the day in green with stock markets in Japan, Singapore and China up 1.3%, 0.6% and 0.3% respectively, are leading the pack of gainers. The major stock indices in the European and US markets ended their previous session on a dismal note. The benchmark indices of US ended their previous session lower by 3.03%.The rupee is trading at 66.22 per US dollar.

Indian stock markets have opened the day on a flattish note. BSE-Sensex is trading up by 22 points (up 0.08%) and NSE-Nifty is trading up by 1.80 points (up 0.02%). S&P BSE Midcap is trading down by 0.2% and S&P BSE Smallcap is trading up by 0.3%. Sectoral indices have opened the day on a mixed note with stocks from oil and gas and automobile sector witnessing selling pressure. However stocks from telecommunication and tobacco sector are witnessing buying interest.

According to a financial daily, the foreign portfolio investors (FPIs) would be relieved from the payment of MAT from Minimum Alternative Tax (MAT) for the years prior to 1st April, 2015. The move is in line with the recommendations of the A.P. Shah committee. Reportedly, the government will introduce clarificatory amendments to the Income Tax (I-T) Act to exempt portfolio investors from MAT in the next session of parliament. The tax department will also issue a circular to its field formations to put on hold all existing demands as well as new demands. But uncertainty persists for 'foreign companies' because according to panel, relief will be provided only to 'FPIs' and not overseas corporate entity.

Major stocks in the pharmaceutical have opened their day in green. As per an articles in Business Standard, Sun Pharmaceutical has completed the acquisition of GlaxoSmithKline's (GSK's) opiates business in Australia. This would strengthen its Active Pharmaceutical Ingredients (API) and analgesic drug segments. The deal was announced in March, but the same was finalized yesterday. Under the deal, GSK's two manufacturing plant in Australia along with inventory will be transferred to Sun Pharma. US is the largest market for opiate-based medicines and the top-five pharmaceutical companies control over 60 per cent share in analgesic drugs made from controlled substances. The acquisition in Australia will thus help Sun Pharmaceuticals in improving its product sourcing and help grow analgesics business.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Indian markets open in green". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 2, 2021 03:36 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS